Effects of Plasmapheresis on the Acetylcholine Receptor Antibody and Clincal Course in Myasthenia Gravis.
- Author:
Geun Ho LEE
1
;
Kwang Woo LEE
Author Information
1. Department of Neurology, College of Medicine, Seoul National University, Korea.
- Publication Type:Original Article
- MeSH:
Acetylcholine*;
Antibodies;
Myasthenia Gravis*;
Plasmapheresis*
- From:Journal of the Korean Neurological Association
1993;11(2):187-194
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
It is known that in myasthenia gravis(MG) the plasmapheresis therapy removes the acetylcholine receptor (AChR) antibodies and other toxins in the serum to cause clinical improvement temporarily. To know the effects of plasmapheresis on AChR antibody and clinical courses the authors checked serially the AChR antibody titers and clinical stages in myasthenia gravis. The plasmapheresis were performed for the therapeutic purposes in seven and elective purposes in three MG subjects. After two, three or four cycles of plasmapheresis, the myasthenic symptoms have dramatically improved in all subjects. However the AChR antibody titers decreased in only four out of ten and the decremental ratio in each case uas rather smaller than being expected. Thus the effects of plasmapheresis could not be explained solely by the decreasing phenomena of AChR antibody titers in MG subjects. Therefore the authors assumed that the clinical severities of MG could be correlated with other types of AChR antibodies that are not checked by the routine @-bungarotoxin binding technique, or the AChR antibodies are secondarily produced in large amount by the mechanism of rebound enhancing activity.
